Lung cancer is a type of cancer that decreases the ability of the lungs to supply oxygen to the bloodstream because of uncontrolled growth of tissues in the lung. Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. On the basis of the size of the tumour cells, lung cancer is broadly divided into small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC).
Market Size and Key Findings
The Global Lung Cancer Drugs Market size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.
Global Lung Cancer Drugs Market Size (In USD Bn)
(2021-2030F)
Market Dynamics
Market Growth Drivers Analysis
The rising prevalence rate of lung cancer is a major driver for the lung cancer drug market. The introduction of new and sophisticated targeted therapies leads to the growth of the market.
Market Restraints
The poor quality of air is giving rise to numerous diseases related to the lungs, which convert into a type of cancer if not treated on time. However, the high cost of lung cancer therapeutics systems and instruments is restraining the growth of the market.
Competitive Landscape
Key Players
Major players in Lung Cancer Drugs Market are Bristol-Myers Squibb Company, Merck & Co., F. Hoffmann-La Roche Ltd, Novartis AG, Pfizer Inc., GlaxoSmithKlin, Vertiv Co., Sanofi-Aventis, Sun Pharmaceuticals Industries and Celgene Corporation
TABLE OF CONTENT
1. Report Description of the Global Lung Cancer Drugs Market
1.1 Research Scope and Assumption
1.2 Objective of the study
1.3 Research Methodology
1.4 Reason to buy the report
2. Global Lung Cancer Drugs Market Executive Summary
2.1 Global Lung Cancer Drugs Market – Industry Snapshot & key buying criteria, 2021-2030
2.2 Market Size, Growth Prospects, and Key findings
3. Market Dynamics of Global Lung Cancer Drugs Market
3.1 Market Growth Drivers Analysis
3.2 Market Restrains Analysis
4. Global Lung Cancer Drugs Market Segmentation
4.1 By disease type
4.1.1 Small cell lung cancer (SCLC)
4.1.2 Non-small cell lung cancer (NSCLC)
4.2 By Drug
4.2.1 Gemzar
4.2.2 Paraplatin
4.2.3 Taxotere
4.2.4 Others
4.3 By End User
4.3.1 Hospitals
4.3.2 Clinics
4.3.3 Others
5. Global Lung Cancer Drugs Market Share
5.1 Market Analysis, Insights, and Forecast – By Revenue
6. Competitive Landscape
6.1 Major Top Market Players
7. Key Company Profiles
7.1 Company 1
7.1.1 Overview
7.1.2 Financial Performance
7.1.3 Product & Services
7.1.4 Strategic initiatives
7.2 Company 2
7.2.1 Overview
7.2.2 Financial Performance
7.2.3 Product & Services
7.2.4 Strategic initiatives
7.3 Company 3
7.3.1 Overview
7.3.2 Financial Performance
7.3.3 Product & Services
7.3.4 Strategic initiatives
7.4 Company 4
7.4.1 Overview
7.4.2 Financial Performance
7.4.3 Product & Services
7.4.4 Strategic initiatives
7.5 Company 5
7.5.1 Overview
7.5.2 Financial Performance
7.5.3 Product & Services
7.5.4 Strategic initiatives
8. Healthcare Policies and Regulatory Landscape
8.1 Healthcare Policies in Global
8.2 Regulatory Framework in Global
8.3 Pricing & Reimbursement Scenario in Global Lung Cancer Drugs Market
9. Factors Driving Future Growth
9.1 New Trends and Development Global Lung Cancer Drugs Market
9.2 Future Opportunities
10. Strategic Recommendations
Segmentation
Lung Cancer Drugs Market Segmentation
By Disease type
Small Cell Lung Cancer (SCLC)
Non-Small Cell Lung Cancer (NSCLC)
By Drug
Gemzar
Paraplatin
Texotere
Others
By End-user
Hospitals
Clinics
Others
Methodology
Why Choose Us
24 * 7 Access to Analyst :
Get your pre and post sales queries resolved by our Subject matter experts.
Customization :
We will assist you to customize the report to fit your research needs.
Assured Quality :
Our prime focus is to provide qualitative and accurate data.
Free sample report :
Feel free to order a sample report before purchase.
Security :
Your personal and confidential information is safe and secured.
